Latest Content

  • A CME-certified text module reviews evolving management of patients with cirrhosis, reduced renal function, genotype 3 HCV infection, and HCV/HIV coinfection, and provides the basis for an ongoing case-based <b><a href='/Hepatitis/Live Events/Meeting Series/HCV Flipped Classroom.aspx' target='_blank'>dinner meeting series</a></b> being presented in several US cities.

    Evolving HCV Management in Harder-to-Treat Populations

    A CME-certified text module reviews evolving management of patients with cirrhosis, reduced renal function, genotype 3 HCV infection, and HCV/HIV coinfection, and provides the basis for an ongoing case-based dinner meeting series being presented in several US cities.
    Date Posted: 5/5/2015
  • Downloadable slides from ONS Congress satellite by experts Joseph D. Tariman, PhD, ANP-BC; Sandra E. Kurtin, RN, MS, AOCN, ANP-C; and Beth Faiman PhD, MSN, APRN-BC, AOCN, that cover available clinical data and optimal care of patients with multiple myeloma within a shared decision making framework.

    Advocacy in Action: Implementing Shared Decision Making in Multiple Myeloma

    Downloadable slides from ONS Congress satellite by experts Joseph D. Tariman, PhD, ANP-BC; Sandra E. Kurtin, RN, MS, AOCN, ANP-C; and Beth Faiman PhD, MSN, APRN-BC, AOCN, that cover available clinical data and optimal care of patients with multiple myeloma within a shared decision making framework.
    Date Posted: 4/30/2015
  • Joyce O’Shaughnessy, MD, reviews current treatment options and provides expert perspective on promising emerging agents for the treatment of HER2-negative metastatic breast cancer, with a particular focus on triple-negative disease.

    Clinical Focus: Treatment for HER2-Negative Metastatic Breast Cancer

    Joyce O’Shaughnessy, MD, reviews current treatment options and provides expert perspective on promising emerging agents for the treatment of HER2-negative metastatic breast cancer, with a particular focus on triple-negative disease.
    Date Posted: 4/29/2015
  • In this interactive presentation, C. Ola Landgren, MD, PhD, discusses the uses of minimal residual disease as a measurement of response to improve outcomes in patients with multiple myeloma.

    The Role of Minimal Residual Disease in Multiple Myeloma

    In this interactive presentation, C. Ola Landgren, MD, PhD, discusses the uses of minimal residual disease as a measurement of response to improve outcomes in patients with multiple myeloma.
    Date Posted: 4/27/2015
  • In this on-demand Webcast—featuring discussion and slides from the 2015 ONS Immunotherapy Satellite Symposium—oncology nursing experts share their insights on  immunotherapy and supporting the patients who receive these emerging cancer treatments. Download a nursing patient education checklist on optimal use of checkpoint inhibitors and management of associated adverse events.

    The Oncology Quiz Game: Understanding Immunotherapies and Their Role in Cancer Care

    In this on-demand Webcast—featuring discussion and slides from the 2015 ONS Immunotherapy Satellite Symposium—oncology nursing experts share their insights on immunotherapy and supporting the patients who receive these emerging cancer treatments. Download a nursing patient education checklist on optimal use of checkpoint inhibitors and management of associated adverse events.
    Date Posted: 4/23/2015
Decision Support
Free
inPractice
Immediate answers to treatment questions
More than just up to date